Literature DB >> 11304544

Characterization of recombinant HPV6 and 11 E1 helicases: effect of ATP on the interaction of E1 with E2 and mapping of a minimal helicase domain.

P W White1, A Pelletier, K Brault, S Titolo, E Welchner, L Thauvette, M Fazekas, M G Cordingley, J Archambault.   

Abstract

To better characterize the enzymatic activities required for human papillomavirus (HPV) DNA replication, the E1 helicases of HPV types 6 and 11 were produced using a baculovirus expression system. The purified wild type proteins and a version of HPV11 E1 lacking the N-terminal 71 amino acids, which was better expressed, were found to be hexameric over a wide range of concentrations and to have helicase and ATPase activities with relatively low values for K(m)(ATP) of 12 microm for HPV6 E1 and 6 microm for HPV11 E1. Interestingly, the value of K(m)(ATP) was increased 7-fold in the presence of the E2 transactivation domain. In turn, ATP was found to perturb the co-operative binding of E1 and E2 to DNA. Mutant and truncated versions of in vitro translated E1 were used to identify a minimal ATPase domain composed of the C-terminal 297 amino acids. This fragment was expressed, purified, and found to be fully active in ATP hydrolysis, single-stranded DNA binding, and unwinding assays, despite lacking the minimal origin-binding domain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304544     DOI: 10.1074/jbc.M101932200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  The inhibitory action of P56 on select functions of E1 mediates interferon's effect on human papillomavirus DNA replication.

Authors:  Paramananda Saikia; Volker Fensterl; Ganes C Sen
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2.

Authors:  Eric A Abbate; James M Berger; Michael R Botchan
Journal:  Genes Dev       Date:  2004-08-02       Impact factor: 11.361

3.  Interactions required for binding of simian virus 40 T antigen to the viral origin and molecular modeling of initial assembly events.

Authors:  Danielle K Reese; Kodangattil R Sreekumar; Peter A Bullock
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 4.  Understanding helicases as a means of virus control.

Authors:  D N Frick; A M I Lam
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

5.  Human papillomavirus E1 helicase interacts with the WD repeat protein p80 to promote maintenance of the viral genome in keratinocytes.

Authors:  Alexandra Côté-Martin; Cary Moody; Amélie Fradet-Turcotte; Claudia M D'Abramo; Michaël Lehoux; Simon Joubert; Guy G Poirier; Benoit Coulombe; Laimonis A Laimins; Jacques Archambault
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

6.  mRNA splicing regulates human papillomavirus type 11 E1 protein production and DNA replication.

Authors:  Wentao Deng; Ge Jin; Biing-Yuan Lin; Brian A Van Tine; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  The E1 proteins.

Authors:  Monika Bergvall; Thomas Melendy; Jacques Archambault
Journal:  Virology       Date:  2013-09-10       Impact factor: 3.616

8.  Development of quantitative and high-throughput assays of polyomavirus and papillomavirus DNA replication.

Authors:  Amélie Fradet-Turcotte; Geneviève Morin; Michaël Lehoux; Peter A Bullock; Jacques Archambault
Journal:  Virology       Date:  2010-01-15       Impact factor: 3.616

9.  Characterization of papillomavirus E1 helicase mutants defective for interaction with the SUMO-conjugating enzyme Ubc9.

Authors:  Amélie Fradet-Turcotte; Karine Brault; Steve Titolo; Peter M Howley; Jacques Archambault
Journal:  Virology       Date:  2009-12-20       Impact factor: 3.616

Review 10.  Targeting human papillomavirus genome replication for antiviral drug discovery.

Authors:  Jacques Archambault; Thomas Melendy
Journal:  Antivir Ther       Date:  2013-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.